// App-Quantinova.ai

e19408 : Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT).

Researchers

Presenter

  • Nilanjan Ghosh

Principal Investigators

  • Bruno Emond

  • Marie-Hlne Lafeuille

  • Aurlie Ct-Sergent

  • Patrick Lefebvre

  • Qing Huang

Medical Centers

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • Analysis Group, Inc., Montreal, QC, Canada

  • Janssen Scientific Affairs, Horsham, PA

Locations

  • United States

  • Canada

Companies

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved